KalVista (KALV) Pharmaceuticals announced that the U.S. Food and Drug Administration has approved EKTERLY, a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema in adult and pediatric patients aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE. KalVista will launch EKTERLY in the U.S. immediately and physicians can begin writing prescriptions today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- Is KALV a Buy, Before Earnings?
- KalVista enters licensing agreement with Pendopharm for sebetralstat
- Optimistic Buy Rating for KalVista Pharmaceuticals Amidst Positive FDA Interactions and Imminent Decision on Sebetralstat
- Stifel calls report of Makary pushing for KalVista CRL ‘highly surprising’
- KalVista selloff on Endpoints report unwarranted, says JonesResearch